Glucocorticoid-induced Osteoporosis and Its Treatment
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Osteoporosis and fractures are frequent and important consequences of glucocorticoid therapy. Many factors contribute to bone loss during glucocorticoid therapy, such as underlying disease, malnutrition, vitamin D insufficiency, hypogonadism, and low body weight. Bone loss occurs particularly in the first few months of glucocorticoid treatment and affects more cancellous than cortical bone, with reduced bone formation and increased bone resorption. The risk of fracture increases rapidly in patients with glucocorticoid therapy. The existence of a threshold is not well defined but the risk of fracture is increased in patients with higher doses of glucocorticoids. Other effects include altered production of gonadal sex hormones, inhibition of intestinal calcium absorption, and enhancement of renal excretion of calcium. Prevention of glucocorticoid-induced osteoporosis is based on general measures such as calcium and vitamin D supplementation, adequate protein intake, regular physical exercise, and specific therapies. Bisphosphonates, which are potent bone resorption inhibitors, have been shown to increase bone mineral density and to decrease fracture risk, so that they represent the first choice in the prevention of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis is a major burden to those whom it affects. It can be prevented provided efficacious preventive measures are introduced early during glucocorticoid treatment. LEVEL OF EVIDENCE: Level V (expert opinion). See the Guidelines for Authors for a complete description of the levels of evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 2×
“The final result of glucocorticoid treatment is an imbalance between bone formation (reduced) and bone resorption (increased).(73) Glucocorticoid treatment is associated with a greater reduction in osteoblastic activity than is postmenopausal osteoporosis, resulting in a low number of trabeculae that are separated by…”
BackgroundThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“also been suggested to be involved in glucocorticoidinduced bone cell apoptosis.(49) Increased osteocyte apoptosis has been suggested to lead to accumulation of bone”
BackgroundA meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Effects of inhaled glucocorticoids on bone density in premenopausal women.
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., Kotlov, T. V., LaHive, K., & LeBoff, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002304 · Cited by 303 · cited 1×
“In one study examining vertebral fracture rate, the risk was higher in patients with inhaled glucocorticoid therapy than in untreated controls, but similar to that of patients treated with beta agonists,(69) suggesting a role of the underlying disease.(24,30,35,37,43,69,74) Some authors agree that inhaled glucocortico…”
ResultSAKAKURA, M., TAKEBE, K., & NAKAGAWA, S. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-40-5-774 · Cited by 261
Reversible gonadotropin Deficiency in Male Cushing's Dusease
LUTON, J.-P., THIEBLOT, P., VALCKE, J.-C., MAHOUDEAU, J. A., & BRICAIRE, H. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-3-488 · Cited by 202 · cited 1×
“follicle-stimulating hormone, and reduce gonadal sex steroid production.(38,60) Loss of muscle strength and reduced physical activity also probably contribute to the bone loss occurring with glucocorticoids.”
Background
Cited by
Cheng, C.-H., Chen, L.-R., & Chen, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031376 · Cited by 595
“Due to its modest efficacy and less effective actions than bisphosphonate, it is not considered as a first-line treatment of GIOP [89,91].”
BackgroundSTOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100
Activity Restriction Increases Deoxypyridinoline Excretion in Hospitalized High-Risk Pregnant Women
Vanderspank, D., Bernier, S. M., Sopper, M. M., Watson, P., & Mottola, M. F. (2014) · Biological Research For Nursing · doi:10.1177/1099800412463120 · Cited by 4
Metadata
- Authors
- Pennisi, P., Trombetti, A., & Rizzoli, R.
- Venue
- Clinical Orthopaedics & Related Research
- Published
- 2006-02
- Volume
- 443
- Pages
- 39-47
- ISSN
- 0009-921X (ISSN-L)
- OpenAlex
- W2034009153
- Cited by
- 36
- References
- 9
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoid-induced Osteoporosis and Its Treatment. https://app.cochat.ai/papers/10.1097/01.blo.0000200238.29931.1f
- The paper
- Pennisi, P., Trombetti, A., & Rizzoli, R. (2006). Glucocorticoid-induced Osteoporosis and Its Treatment. Clinical Orthopaedics & Related Research. https://doi.org/10.1097/01.blo.0000200238.29931.1f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.